%	O
%	O
TITLE	O

TERT	O
promoter	O
hot	O
spot	O
mutations	O
are	O
frequent	O
in	O
Indian	O
cervical	O
and	O
oral	O
squamous	O
cell	O
carcinomas	O
.	O

%	O
%	O
ABSTRACT	O

Squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
uterine	O
cervix	O
and	O
oral	O
cavity	O
are	O
most	O
common	O
cancers	O
in	O
India	B-Study_Location
.	O

Telomerase	O
reverse	O
transcriptase	O
(	O
TERT	O
)	O
overexpression	O
is	O
one	O
of	O
the	O
hallmarks	O
for	O
cancer	O
,	O
and	O
activation	O
through	O
promoter	O
mutation	O
C228T	O
and	O
C250T	O
has	O
been	O
reported	O
in	O
variety	O
of	O
tumors	O
and	O
often	O
shown	O
to	O
be	O
associated	O
with	O
aggressive	O
tumors	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
these	O
two	O
hot	O
spot	O
mutations	O
in	O
181	B-Study_Cohort
primary	I-Study_Cohort
tumors	I-Study_Cohort
of	I-Study_Cohort
the	I-Study_Cohort
uterine	I-Study_Cohort
cervix	I-Study_Cohort
and	I-Study_Cohort
oral	I-Study_Cohort
cavity	I-Study_Cohort
by	O
direct	O
DNA	O
sequencing	O
and	O
correlated	O
with	O
patient	O
'	O
s	O
clinicopathological	O
characteristics	O
.	O

We	O
found	O
relatively	O
high	O
frequency	O
of	O
TERT	O
hot	O
spot	O
mutations	O
in	O
both	O
cervical	O
[	O
21	O
.	O
4Â	O
%	O
(	O
30	O
/	O
140	O
)	O
]	O
and	O
oral	O
[	O
31	O
.	O
7Â	O
%	O
(	O
13	O
/	O
41	O
)	O
]	O
squamous	O
cell	O
carcinomas	O
.	O

In	O
cervical	O
cancer	O
,	O
TERT	O
promoter	O
mutations	O
were	O
more	O
prevalent	B-Incidence_or_Prevalence
(	O
25Â	O
%	O
)	O
in	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
-	O
negative	O
cases	O
compared	O
to	O
HPV	O
-	O
positive	O
cases	O
(	O
20	O
.	O
6Â	O
%	O
)	O
,	O
and	O
both	O
TERT	O
promoter	O
mutation	O
and	O
HPV	O
infection	O
were	O
more	O
commonly	O
observed	O
in	O
advanced	O
stage	O
tumors	O
(	O
77Â	O
%	O
)	O
.	O

Similarly	O
,	O
the	O
poor	O
and	O
moderately	O
differentiated	O
tumors	O
of	O
the	O
uterine	O
cervix	O
had	O
both	O
the	O
TERT	O
hot	O
spot	O
mutations	O
and	O
HPV	O
(	O
16	O
and	O
18	O
)	O
at	O
higher	O
frequency	O
(	O
95	O
.	O
7Â	O
%	O
)	O
.	O

Interestingly	O
,	O
we	O
observed	O
eight	O
homozygous	O
mutations	O
(	O
six	O
228TT	O
and	O
two	O
250TT	O
)	O
only	O
in	O
cervical	O
tumors	O
,	O
and	O
all	O
of	O
them	O
were	O
found	O
to	O
be	O
positive	O
for	O
high	O
-	O
risk	O
HPV	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
from	O
India	B-Study_Location
reporting	O
high	O
prevalence	B-Incidence_or_Prevalence
of	O
TERT	O
promoter	O
mutations	O
in	O
primary	O
tumors	O
of	O
the	O
uterine	O
cervix	O
and	O
oral	O
cavity	O
.	O

Our	O
results	O
suggest	O
that	O
TERT	O
reactivation	O
through	O
promoter	O
mutation	O
either	O
alone	O
or	O
in	O
association	O
with	O
the	O
HPV	O
oncogenes	O
(	O
E6	O
and	O
E7	O
)	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
carcinogenesis	O
of	O
cervical	O
and	O
oral	O
cancers	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Sample	B-HPV_Sample_Type
collection	O
and	O
DNA	O
extraction	O

The	O
Institutional	O
Ethics	O
Committee	O
,	O
Government	O
Arignar	O
Anna	O
Memorial	O
Cancer	O
Hospital	O
,	O
Kancheepuram	O
(	O
No	O
.	O

101041	O
/	O
e1	O
/	O
2009	O
-	O
2	O
)	O
,	O
and	O
Madras	O
Medical	O
College	O
,	O
Chennai	O
(	O
No	O
.	O

04092010	O
)	O
,	O
approved	O
the	O
present	O
study	O
.	O

Cervical	B-HPV_Sample_Type
and	I-HPV_Sample_Type
oral	I-HPV_Sample_Type
cancer	I-HPV_Sample_Type
samples	I-HPV_Sample_Type
were	O
collected	O
following	O
the	O
Institutional	O
Ethical	O
Committee	O
(	O
IEC	O
)	O
guidelines	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
,	O
after	O
explaining	O
about	O
the	O
research	O
study	O
.	O

For	O
the	O
illiterate	O
patients	O
,	O
the	O
study	O
was	O
verbal	O
-	O
ly	O
explained	O
and	O
consent	O
was	O
obtained	O
with	O
their	O
thumb	O
im	O
-	O
pression	O
.	O

Tumor	O
samples	B-HPV_Sample_Type
were	O
collected	O
from	O
Government	O
Royapettah	O
Hospital	O
,	O
Institute	O
of	O
Social	O
Obstetrics	O
and	O
Government	O
Kasturba	O
Gandhi	O
Hospital	O
for	O
Women	O
and	O
Children	O
in	O
Chennai	O
and	O
Arignar	O
Anna	O
Memorial	O
Cancer	O
Hospital	O
and	O
Research	O
Institute	O
,	O
Kancheepuram	O
.	O

Genomic	O
DNA	O
from	O
a	O
tissue	B-HPV_Sample_Type
sample	I-HPV_Sample_Type
was	O
isolated	O
by	O
the	O
conventional	O
Proteinase	O
K	O
digestion	O
and	O
Phenol	O
:	O
Chloroform	O
:	O
Isoamyl	O

alcohol	O
(	O
PCI	O
)	O
extraction	O
method	O
.	O

The	O
DNA	O
samples	B-HPV_Sample_Type
were	O
dis	O
-	O
solved	O
in	O
1×	O
TE	O
buffer	O
and	O
quantified	O
using	O
NanoDrop2000	O
UV	O
-	O
Vis	O
spectrophotometer	O
(	O
Thermo	O
Scientific	O
,	O
USA	O
)	O
.	O

The	O
in	O
-	O
tegrity	O
of	O
DNA	O
was	O
verified	O
by	O
0	O
.	O
7	O
%	O
agarose	O
gel	O
electrophoresis	O
.	O

PCR	B-HPV_Lab_Technique
amplification	O
and	O
sequencing	O
of	O
TERT	O
gene	O
promoter	O

A	O
total	O
of	O
181	O
SCC	O
tumor	O
DNA	O
samples	B-HPV_Sample_Type
(	O
140	O
uterine	O
cervix	O
and	O
41	O
oral	O
cavity	O
)	O
were	O
PCR	B-HPV_Lab_Technique
amplified	O
using	O
the	O
TERT	O
gene	O
pr	O
omo	O
t	O
er	O
-	O
sp	O
ec	O
i	O
fic	O
p	O
r	O
i	O
mer	O
s	O
TERT	O
Fw	O
:	O
5	O
′	O
-	O
M	O
13	O
-	O
GGCCGATTCGACCTCTCTC	O
-	O
3′	O
and	O
TERT	O
Rw	O
:	O
5′	O
-	O

CAGCGCTGCCTGAAACTCG	O
-	O
3′	O
(	O
where	O
M13	O
in	O
the	O
TERT	O
Fw	O
is	O
the	O
universal	O
sequencing	O
primer	O
5′	O
-	O
tgtaaaacgacggccagt	O
-	O
3′	O
)	O
.	O

Polymerase	B-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O
was	O
performed	O
in	O
a	O
total	O
of	O
60	O
-	O
μL	O
volume	O
containing	O
200	O
ng	O
of	O
genomic	O
DNA	O
,	O
1X	O
PCR	B-HPV_Lab_Technique
buffer	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
100	O
μM	O
dNTP	O
(	O
Takara	O
,	O
Japan	O
)	O
,	O
2	O
.	O
5	O
units	O
of	O
AmpliTaq	O
Gold	O
(	O
Applied	O
Biosystems	O
Inc	O
.	O
,	O
USA	O
)	O
,	O
200	O
nM	O
primers	O
(	O
Sigma	O
,	O
India	O
)	O
,	O
and	O
6	O
%	O
1	O
,	O
2	O
-	O
propanediol	O
as	O
an	O
enhancer	O
for	O
amplifying	O
GC	O
-	O
rich	O
sequence	O
[	O
]	O
.	O

Thermal	O
cycling	O
conditions	O
for	O
PCR	B-HPV_Lab_Technique
were	O
5	O
min	O
at	O
95	O
°C	O
once	O
followed	O
by	O
30	O
s	O
at	O
95	O
°C	O
,	O
45	O
s	O
at	O
60	O
°C	O
,	O
and	O
45	O
s	O
at	O
72	O
°C	O
for	O
10	O
cycles	O
and	O
30	O
cycles	O
of	O
30	O
s	O
at	O
95	O
°C	O
,	O
45	O
s	O
at	O
60	O
°C	O
and	O
30	O
s	O
(	O
with	O
a	O
5	O
-	O
s	O
increase	O
in	O
each	O
cycle	O
)	O
at	O
72	O
°C	O
and	O
final	O
extension	O
for	O
7	O
min	O
at	O
72	O
°C	O
.	O

The	O
PCR	B-HPV_Lab_Technique
products	O
(	O
378	O
bp	O
)	O
were	O
electrophoresed	O
in	O
2	O
%	O
agarose	O
gel	O
and	O
purified	O
by	O
QIAquick	O
PCR	B-HPV_Lab_Technique
purification	O
kit	O
(	O
Qiagen	O
,	O
USA	O
)	O
.	O

The	O
amplicons	O
were	O
then	O
subjected	O
to	O
Sanger	O
sequenc	O
-	O
ing	O
(	O
Macrogen	O
Inc	O
.	O
,	O
Seoul	O
,	O
South	O
Korea	O
)	O
.	O

Screening	O
for	O
high	O
-	O
risk	O
HPV	O
16	O
and	O
HPV	O
18	O
by	O
real	B-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique

HPV	O
16	O
and	O
HPV	O
18	O
E6	O
-	O
specific	O
primers	O
and	O
FAM	O
-	O
labeled	O
MGB	O
probes	O
(	O
Table	O
)	O
were	O
custom	O
designed	O
and	O
purchased	O
from	O
Invitrogen	O
(	O
USA	O
)	O
.	O

The	O
β	O
-	O
globin	O
gene	O
served	O
as	O
an	O
inter	O
-	O
nal	O
control	O
.	O

No	O
template	O
negative	O
control	O
was	O
also	O
included	O
in	O
all	O
the	O
reaction	O
plates	O
.	O

The	O
reaction	O
mixture	O
(	O
10	O
μL	O
)	O
consisted	O
of	O
20	O
ng	O
of	O
tissue	B-HPV_Sample_Type
DNA	O
,	O
5	O
μL	O
of	O
2X	O
master	O
mix	O
(	O
Roche	O
,	O
USA	O
)	O
,	O
900	O
nM	O
of	O
each	O
primer	O
,	O
and	O
250	O
nM	O
of	O
probe	O
.	O

A	O
sep	O
-	O
arate	O
reaction	O
was	O
set	O
up	O
for	O
HPV	O
16	O
and	O
HPV	O
18	O
amplifica	O
-	O
tion	O
,	O
and	O
polymerase	B-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
was	O
carried	O
out	O
in	O
ABI	O
7900HT	O
Real	O
Time	O
PCR	B-HPV_Lab_Technique
System	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
)	O
with	O
the	O
following	O
thermal	O
cycling	O
conditions	O
:	O
50	O
°C	O
for	O
2	O
min	O
followed	O
by	O
enzyme	O
activation	O
step	O
95	O
°C	O
for	O
10	O
min	O
and	O
40	O
cycles	O
of	O
95	O
°C	O
for	O
15	O
s	O
and	O
60	O
°C	O
for	O
1	O
min	O
.	O

Statistical	O
analysis	O

Statistical	O
analyses	O
were	O
performed	O
using	O
GraphPad	O
Prism	O
version	O
6	O
and	O
the	O
Fisher	O
exact	O
test	O
with	O
p	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

Table	O
1	O
Sequence	O
of	O
HPV	O
type	O
-	O
specific	O
primers	O
/	O
probes	O
used	O
for	O
HPV	O
typing	O
and	O
β	O
-	O
globin	O
gene	O
specific	O
primers	O
/	O
probe	O
for	O
control	O

Gene	O
Forward	O
and	O
Reverse	O
Primers	O
FAM	O
-	O
labeled	O
MGB	O
probe	O

HPV	O
16	O
F	O
-	O
5′	O
-	O
CTGCAATGTTTCAGGACCCA	O
-	O
3′	O
5′	O
-	O
CCAGAAAGTTACCACAG	O
-	O
3′	O
R	O
-	O
5′	O
-	O
TCATGTATAGTTGTTTGCAGCTCTGT	O
-	O
3′	O

HPV	O
18	O
F	O
-	O
5′	O
-	O
AAACCGTTGAATCCAGCAGAA	O
-	O
3′	O
5′	O
-	O
CACTATAGAGGCCAGTG	O
-	O
3′	O
R	O
-	O
5′	O
-	O
GTCGTTCCTGTCGTGCTCG	O
-	O
3′	O

β	O
-	O
Globin	O
F	O
-	O
5′	O
-	O
GGATCTGTCCACTCCTGATGCTG	O
-	O
3′	O
5′	O
-	O
CTAAGGTGAAGGCTCAT	O
-	O
3′	O
R	O
-	O
5′	O
-	O
TCACTCAGTGTGGCAAAGGTGC	O
-	O
3′	O

